China-based Shenzhen Kangtai Biological Products Co., Ltd (SHE: 300601) has formed a vaccine-focused partnership with UK pharmaceutical giant AstraZeneca (NASDAQ: AZN). The collaboration includes the establishment of a joint venture (JV) in Beijing aimed at developing and manufacturing novel vaccines for China and emerging markets.
Joint Venture Details
The JV marks AstraZeneca’s first and only vaccine manufacturing plant in China. It has a registered capital of USD 50 million, with ownership equally split between the two companies. This strategic move underscores AstraZeneca’s commitment to expanding its presence in the Chinese vaccine market while leveraging local expertise and resources.
Strategic Significance
The partnership is designed to address the growing demand for innovative vaccines in China and other emerging markets. By combining Shenzhen Kangtai’s local market insights and manufacturing capabilities with AstraZeneca’s global research and development expertise, the joint venture aims to accelerate the development of novel vaccines tailored to regional health needs.-Fineline Info & Tech
Leave a Reply